Single User License
INR 133960
Site License
INR 267920
Corporate User License
INR 401880

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Acute Heart Failure-Pipeline Review, H2 2015

Acute Heart Failure-Pipeline Review, H2 2015


  • Products Id :- GMDHC6881IDB
  • |
  • Pages: 76
  • |
  • July 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Acute Heart Failure-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Acute Heart Failure-Pipeline Review, H2 2015', provides an overview of the Acute Heart Failure's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Heart Failure and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Acute Heart Failure

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Acute Heart Failure and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Acute Heart Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Acute Heart Failure pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Acute Heart Failure

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Acute Heart Failure pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Acute Heart Failure Overview 7

Therapeutics Development 8

Pipeline Products for Acute Heart Failure-Overview 8

Pipeline Products for Acute Heart Failure-Comparative Analysis 9

Acute Heart Failure-Therapeutics under Development by Companies 10

Acute Heart Failure-Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Acute Heart Failure-Products under Development by Companies 14

Acute Heart Failure-Companies Involved in Therapeutics Development 15

Amgen Inc. 15

Angion Biomedica Corp. 16

Bayer AG 17

Lee's Pharmaceutical Holdings Limited 18

Novartis AG 19

Nyken BV 20

Ono Pharmaceutical Co., Ltd. 21

PhaseBio Pharmaceuticals, Inc. 22

Trevena, Inc. 23

Acute Heart Failure-Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Drug Profiles 33

ANG-4011-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

BR-5489-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

cenderitide-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

istaroxime-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

NYK-1112-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

omecamtiv mecarbil-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

ONO-4232-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

PB-1046-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

serelaxin-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

TRV-027-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

TRV-120023-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

ularitide-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Acute Heart Failure-Recent Pipeline Updates 53

Acute Heart Failure-Dormant Projects 66

Acute Heart Failure-Discontinued Products 67

Acute Heart Failure-Product Development Milestones 68

Featured News & Press Releases 68

May 22, 2015: Cardiorentis Completes Enrollment in Pivotal Phase III Clinical Trial of Ularitide for Acute Heart Failure 68

Mar 09, 2015: Trevena completes interim analysis and announces plans for ongoing Phase 2b BLAST-AHF trial of TRV027 in acute heart failure 68

Feb 03, 2015: TRV027 Phase 2b BLAST-AHF Trial Design Published in Journal of the American College of Cardiology: Heart Failure 69

Oct 16, 2014: Cardiorentis AG and Roche Announce Collaboration to Establish Therapeutic Impact of Ularitide 70

Oct 09, 2014: Capricor Therapeutics Announces Plans to Pursue a Cenderitide Clinical Program and Enters Into Research Support Agreement With Insulet Corporation 70

Aug 05, 2014: Trevena Granted Key U.S. Method of Use Patent for TRV027 71

May 23, 2014: Novartis provides update on EU marketing authorization application for RLX030 in acute heart failure 71

May 19, 2014: Trevena Highlights Phase 2b-BLAST AHF Trial for TRV027 at the European Society of Cardiology Heart Failure 2014 Meeting 72

May 16, 2014: FDA issues Complete Response Letter for RLX030 for acute heart failure 73

Mar 27, 2014: Novartis to work with FDA on path forward for RLX030 for acute heart failure following Advisory Committee outcome 73

Appendix 75

Methodology 75

Coverage 75

Secondary Research 75

Primary Research 75

Expert Panel Validation 75

Contact Us 75

Disclaimer 76

List of Tables

Number of Products under Development for Acute Heart Failure, H2 2015 8

Number of Products under Development for Acute Heart Failure-Comparative Analysis, H2 2015 9

Number of Products under Development by Companies, H2 2015 10

Comparative Analysis by Late Stage Development, H2 2015 11

Comparative Analysis by Clinical Stage Development, H2 2015 12

Comparative Analysis by Early Stage Development, H2 2015 13

Products under Development by Companies, H2 2015 14

Acute Heart Failure-Pipeline by Amgen Inc., H2 2015 15

Acute Heart Failure-Pipeline by Angion Biomedica Corp., H2 2015 16

Acute Heart Failure-Pipeline by Bayer AG, H2 2015 17

Acute Heart Failure-Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2015 18

Acute Heart Failure-Pipeline by Novartis AG, H2 2015 19

Acute Heart Failure-Pipeline by Nyken BV, H2 2015 20

Acute Heart Failure-Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 21

Acute Heart Failure-Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2015 22

Acute Heart Failure-Pipeline by Trevena, Inc., H2 2015 23

Assessment by Monotherapy Products, H2 2015 24

Number of Products by Stage and Target, H2 2015 26

Number of Products by Stage and Mechanism of Action, H2 2015 28

Number of Products by Stage and Route of Administration, H2 2015 30

Number of Products by Stage and Molecule Type, H2 2015 32

Acute Heart Failure Therapeutics-Recent Pipeline Updates, H2 2015 53

Acute Heart Failure-Dormant Projects, H2 2015 66

Acute Heart Failure-Discontinued Products, H2 2015 67

List of Figures

Number of Products under Development for Acute Heart Failure, H2 2015 8

Number of Products under Development for Acute Heart Failure-Comparative Analysis, H2 2015 9

Number of Products under Development by Companies, H2 2015 10

Comparative Analysis by Late Stage Development, H2 2015 11

Comparative Analysis by Clinical Stage Development, H2 2015 12

Comparative Analysis by Early Stage Products, H2 2015 13

Assessment by Monotherapy Products, H2 2015 24

Number of Products by Top 10 Targets, H2 2015 25

Number of Products by Stage and Top 10 Targets, H2 2015 25

Number of Products by Top 10 Mechanism of Actions, H2 2015 27

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 27

Number of Products by Top 10 Routes of Administration, H2 2015 29

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 29

Number of Products by Top 10 Molecule Types, H2 2015 31

Number of Products by Stage and Top 10 Molecule Types, H2 2015 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Amgen Inc.

Angion Biomedica Corp.

Bayer AG

Lee's Pharmaceutical Holdings Limited

Novartis AG

Nyken BV

Ono Pharmaceutical Co., Ltd.

PhaseBio Pharmaceuticals, Inc.

Trevena, Inc.

Acute Heart Failure Therapeutic Products under Development, Key Players in Acute Heart Failure Therapeutics, Acute Heart Failure Pipeline Overview, Acute Heart Failure Pipeline, Acute Heart Failure Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com